Back
Compare AU
Compare IESG vs. DRUG
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the iShares Core MSCI Australia Esg ETF (IESG) and the Betashares Global Healthcare Currency Hedged ETF (DRUG). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
IESG | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 68 | 67 |
Median incremental investment | $1,650.51 | $740.50 |
Median investment frequency | Monthly | Monthly |
Median total investment | $6,600.17 | $1,935.72 |
Average age group | 26 - 35 | > 35 |
Key Summary
IESG | DRUG | |
|---|---|---|
Strategy | IESG.AX was created on 2021-06-02 by iShares. The fund's investment portfolio concentrates primarily on total market equity. The ETF currently has 407.73m in AUM and 81 holdings. The Fund aims to provide investors with the performance of an index, before fees and expenses. The objective of the Fund is to provide exposure to large, mid and small cap segments of the Australian market with better sustainability credentials relative to their sector peers | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. |
Top 3 holdings | COMMONWEALTH BANK OF AUSTRALIA (13.69 %) WESFARMERS LTD (9.57 %) CSL LTD (8.35 %) | BRL - BRAZILIAN REAL (0 %) AUD - AUSTRALIA DOLLAR (0 %) CHF - SWISS FRANC (0 %) |
Top 3 industries | Financials (29.77 %) Materials (18.88 %) Consumer Discretionary (10.77 %) | Other (75.91 %) Communication Services (33.53 %) Health Care (23.80 %) |
Top 3 countries | Australia (95.54 %) New Zealand (2.29 %) United States (2.18 %) | United States (71.71 %) Switzerland (8.14 %) Denmark (6.30 %) |
Management fee | 0.01 % | 0.57 % |
Key Summary
IESG | DRUG | |
|---|---|---|
Issuer | iShares | BetaShares |
Tracking index | MSCI Australia IMI Custom ESG Leaders Index - AUD - Benchmark TR Gross | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD |
Asset class | ETF | ETF |
Management fee | 0.01 % | 0.57 % |
Price | $30.95 | $8.60 |
Size | $393.082 million | $168.713 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 2.27 % | 1.97 % |
Market | ASX | ASX |
First listed date | 03/06/2021 | 08/08/2016 |
Purchase fee | $6.50 | $6.50 |
Community Stats
IESG | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 68 | 67 |
Median incremental investment | $1,650.51 | $740.50 |
Median investment frequency | Monthly | Monthly |
Median total investment | $6,600.17 | $1,935.72 |
Average age group | 26 - 35 | > 35 |
Pros and Cons
IESG | DRUG | |
|---|---|---|
Pros |
|
|
Cons |
|
|
IESG | DRUG |
|---|---|
Higher exposure to AU market | Lower exposure to AU market |
Lower exposure to US market | Higher exposure to US market |
Lower management fee | Higher management fee |
Lower price growth | Higher price growth |
Higher distribution yield | Lower distribution yield |